Iron Metabolism & Hepcidin

Iron sits at a biological knife-edge. It is indispensable: every hemoglobin molecule needs four iron atoms to bind oxygen, and dozens of enzymes — from the mitochondrial cytochromes of oxidative phosphorylation to ribonucleotide reductase, which makes DNA — depend on iron's ability to flip between the ferrous (Fe²⁺) and ferric (Fe³⁺) states. But that same redox reactivity makes free iron dangerous. Unbound iron catalyzes the Fenton reaction, generating hydroxyl radicals that shred lipids, proteins, and DNA. The whole architecture of iron metabolism exists to keep iron bound — escorted at every step by carrier and storage proteins — while still delivering enough of it to the 200 billion new red blood cells the marrow builds each day.

Crucially, mammals have no regulated way to get rid of iron. We lose a fixed 1-2 mg per day through shed enterocytes, desquamated skin, and small amounts of bleeding, and there is no hormone, no transporter, and no organ that excretes iron on demand. Total body iron — about 3-4 grams in an adult, roughly two-thirds of it circulating in hemoglobin — is therefore policed almost entirely at the point of entry and release. This is the conceptual key to the whole system: if you cannot turn off the drain, you must control the tap. The tap is ferroportin, and the hand on the tap is hepcidin.

The daily iron cycle

Most of the iron you use today never came from your plate. The marrow consumes roughly 20-25 mg of iron daily to synthesize hemoglobin, yet the gut absorbs only 1-2 mg. The other ~95% comes from recycling. Macrophages in the spleen and liver phagocytose senescent red cells — each erythrocyte lives about 120 days — and strip the iron from heme using the enzyme heme oxygenase. That salvaged iron is either stockpiled as ferritin inside the macrophage or exported through ferroportin into the plasma, where it is captured by transferrin and ferried back to the marrow. The body essentially runs a closed loop, topped up by a trickle of dietary intake.

Dietary iron itself comes in two forms. Heme iron, from meat, is absorbed efficiently and enters enterocytes largely intact. Non-heme iron (plant sources, fortified foods) is mostly ferric (Fe³⁺) and must first be reduced to ferrous (Fe²⁺) by the brush-border ferrireductase duodenal cytochrome b, then carried into the enterocyte by the divalent metal transporter DMT1. Inside the cell, iron can be stored as ferritin and lost when that enterocyte sloughs off two or three days later, or it can be exported across the basolateral membrane by ferroportin into the bloodstream. Vitamin C boosts non-heme absorption by keeping iron reduced; tannins, phytates, and calcium inhibit it. Whether absorbed iron actually reaches the blood depends on one thing: whether ferroportin is still there.

Ferroportin and hepcidin: the gate and the gatekeeper

Ferroportin is the only known protein that moves iron out of a mammalian cell. It is concentrated exactly where iron needs to leave: the basolateral surface of duodenal enterocytes (exporting newly absorbed dietary iron), the membrane of macrophages (exporting recycled iron), and hepatocytes (exporting stored iron). If ferroportin is on the membrane, iron flows out into plasma. If it is gone, iron is stranded inside the cell regardless of how much was absorbed or salvaged.

Hepcidin is the hormone that removes it. Synthesized by hepatocytes as the gene HAMP and secreted into the blood as a compact 25-amino-acid peptide, hepcidin circulates to ferroportin-bearing cells, binds ferroportin directly, and triggers its ubiquitination, internalization, and lysosomal degradation. (It also occludes the channel directly, an even faster effect.) Within hours of a hepcidin surge, surface ferroportin is destroyed, iron export collapses, dietary absorption is throttled, macrophage iron release is blocked, and serum iron falls. When hepcidin is suppressed, ferroportin accumulates, iron pours out of stores and the gut, and serum iron and transferrin saturation rise. The entire systemic iron level is set by this single ligand-receptor pair.

The name itself encodes the original discovery: hepcidin was first isolated as an antimicrobial peptide (hep- for hepatic, -cidin for its bactericidal activity). That is no accident. Many pathogens scavenge host iron to grow, so withholding iron from the plasma — "nutritional immunity" — is an ancient defense. The hormone that hides iron from the body's own tissues evolved, in part, to hide it from invaders.

What turns hepcidin up and down

Four signals converge on hepcidin transcription, and they make physiological sense once you remember the goal: keep iron available for red-cell production, but not so abundant that it overloads tissues or feeds microbes.

• Iron stores (up). When the liver senses high circulating and stored iron — sensed through the BMP6 / HJV (hemojuvelin) / SMAD pathway and the HFE–transferrin receptor complex — it raises hepcidin. More iron, more hepcidin, less absorption. This is the negative-feedback loop that normally keeps body iron stable.
• Inflammation (up). Interleukin-6 (IL-6) signals through JAK2/STAT3 to induce hepcidin within hours. Infection or chronic inflammation slams the iron gate shut, lowering serum iron to starve pathogens — and incidentally causing anemia of inflammation.
• Erythropoietic demand (down). When the marrow is making red cells hard — after bleeding, or under erythropoietin (EPO) stimulation — erythroblasts secrete the hormone erythroferrone, which suppresses hepcidin. Ferroportin survives, iron floods out to feed hemoglobin synthesis.
• Hypoxia (down). Low oxygen, sensed via HIF and the EPO response, also lowers hepcidin, mobilizing iron for the extra red cells needed at altitude or in anemia.

Notice the conflict built into the system: erythropoietic drive says "release iron," but inflammation says "hide iron." When both are present — as in the anemia of chronic kidney disease or cancer — inflammation usually wins, hepcidin stays high, and the marrow is starved of iron even while stores sit full. This is "functional iron deficiency," and it is why simply giving oral iron often fails in inflammatory disease: the gut won't absorb it, because ferroportin keeps getting destroyed.

Reading the iron panel

The clinical power of this model is that a handful of blood tests — serum iron, transferrin saturation, ferritin, and increasingly hepcidin itself — let you locate where a patient sits on the iron map. The single most useful distinction in everyday practice is separating true iron deficiency from the anemia of inflammation, because their treatments are opposite: one needs iron, the other needs the underlying inflammation controlled (and may be worsened by iron).

Iron deficiency anemia versus anemia of inflammation (anemia of chronic disease)

Parameter	Iron deficiency anemia	Anemia of inflammation
Hepcidin	Low (suppressed)	High (IL-6 driven)
Ferroportin on cells	Preserved	Degraded
Serum iron	Low	Low
Serum ferritin	Low (<30 ng/mL)	Normal or high
Transferrin / TIBC	High (up-regulated)	Low or normal
Transferrin saturation	Low	Low to normal
Body iron stores	Depleted	Normal or increased (trapped)
Response to oral iron	Good	Poor (absorption blocked)

The trap is that both show a low serum iron, so a clinician who looks only at serum iron is misled. Ferritin and hepcidin tell the truth: in true deficiency the stores are empty and hepcidin is off, so any absorbed iron sails through; in inflammation the stores are full but locked, and hepcidin is high, so iron is present but inaccessible. A ferritin below 30 ng/mL is highly specific for depleted iron stores; a low serum iron with a normal-to-high ferritin should make you think inflammation, not deficiency.

When the hepcidin–ferroportin axis breaks

Because hepcidin sets the iron level, diseases of iron balance map cleanly onto hepcidin being inappropriately low or high.

• Hereditary hemochromatosis (hepcidin too low). Mutations in HFE (most commonly C282Y homozygosity), or in HJV, HAMP, or transferrin receptor 2, cripple the liver's iron-sensing pathway. Hepcidin stays inappropriately low, ferroportin never gets shut off, and the gut absorbs iron unchecked for decades. Iron deposits in the liver (cirrhosis, hepatocellular carcinoma), pancreas (diabetes — historically "bronze diabetes"), heart (cardiomyopathy, arrhythmia), joints, and skin. Treatment is therapeutic phlebotomy: removing blood forces the marrow to draw down stored iron, gradually unloading the body.
• Iron-refractory iron deficiency anemia (IRIDA, hepcidin too high). Loss-of-function mutations in TMPRSS6 (matriptase-2, which normally dampens hepcidin) leave hepcidin pathologically high from birth. Ferroportin is chronically degraded, oral iron is not absorbed, and the anemia resists oral and even partly intravenous iron — the mirror image of hemochromatosis.
• Anemia of inflammation (hepcidin too high, acquired). Chronic infection, autoimmune disease, kidney disease, and cancer raise IL-6 and hepcidin, sequestering iron in macrophages. Emerging treatments aim directly at this axis: hepcidin antagonists, anti-IL-6 agents, and ferroportin-stabilizing antibodies.
• Transfusional iron overload. Patients with thalassemia or chronic transfusion needs receive iron faster than they can hide or use it — each unit of blood carries ~200-250 mg of iron, and with no excretory route it accumulates relentlessly. Iron chelators (deferoxamine, deferasirox, deferiprone) bind iron and allow it to be excreted, doing artificially what the body cannot.

The big picture

Iron metabolism is one of the cleanest examples in physiology of a system built around a single regulated valve. The body cannot dump iron, so it must guard the entrance. Ferroportin is that entrance; hepcidin is the lock. Every clinical iron problem — deficiency, overload, the anemia that shadows chronic disease — can be read as ferroportin being open when it should be closed, or closed when it should be open. Understanding the hepcidin–ferroportin axis turns a confusing iron panel into a map, and it is reshaping treatment, from hepcidin-mimetics for hemochromatosis to hepcidin-blockers for the anemia of chronic disease.

This article is educational and is not medical advice. Iron studies and anemia require interpretation by a qualified clinician; do not start, stop, or dose iron or chelation therapy on your own.